SPIA
BOLT icon

Steward Partners Investment Advisory’s Bolt Biotherapeutics BOLT Stock Holding History

Steward Partners Investment Advisory’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50
Closed -$750 – 3756
2024
Q2 		$750 Buy
+50
New +$986 ﹤0.01% 3427

Other funds holding BOLT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Steward Partners Investment Advisory's BOLT Position: Q3 2024 in Review

Steward Partners Investment Advisory sold out of Bolt Biotherapeutics (BOLT) in Q3 2024, closing a stake of 50 shares — an estimated $750 sold.

Steward Partners Investment Advisory first reported a position in BOLT in Q2 2024 and held it in 1 quarter. The position peaked at $750 in Q2 2024. 32 funds tracked by Wall St. Rank hold BOLT as of Q3 2024.

  • Steward Partners Investment Advisory reported no remaining Bolt Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 50 Bolt Biotherapeutics shares in Q3 2024, an estimated $750.
  • Steward Partners Investment Advisory first reported a position in Bolt Biotherapeutics in Q2 2024 and held it in 1 quarter.
  • Steward Partners Investment Advisory's Bolt Biotherapeutics position peaked at $750 in Q2 2024.
  • 32 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2024.

Based on Steward Partners Investment Advisory's 13F filing for Q3 2024, filed 14 Nov 2024.